Truist Financial Corp Boosts Stock Position in Astera Labs, Inc. $ALAB

Truist Financial Corp grew its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 10.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,603 shares of the company’s stock after acquiring an additional 3,541 shares during the period. Truist Financial Corp’s holdings in Astera Labs were worth $6,422,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nordea Investment Management AB purchased a new stake in shares of Astera Labs during the fourth quarter worth $2,028,000. Geneva Partners LLC purchased a new stake in shares of Astera Labs in the third quarter worth $1,876,000. Numerai GP LLC raised its position in shares of Astera Labs by 153.1% in the third quarter. Numerai GP LLC now owns 13,212 shares of the company’s stock worth $2,587,000 after buying an additional 7,992 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Astera Labs by 289.5% in the third quarter. Handelsbanken Fonder AB now owns 126,200 shares of the company’s stock worth $24,710,000 after buying an additional 93,800 shares in the last quarter. Finally, Paragon Advisors LLC purchased a new stake in shares of Astera Labs in the third quarter worth $1,829,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Astera Labs Trading Up 2.1%

ALAB opened at $199.79 on Friday. The company has a market cap of $34.25 billion, a P/E ratio of 134.99, a P/E/G ratio of 3.30 and a beta of 3.35. The business’s 50-day moving average price is $143.77 and its 200-day moving average price is $153.99. Astera Labs, Inc. has a 12 month low of $69.26 and a 12 month high of $262.90.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.54 by $0.07. The firm had revenue of $308.36 million for the quarter, compared to the consensus estimate of $292.19 million. Astera Labs had a return on equity of 18.49% and a net margin of 26.72%.The company’s quarterly revenue was up 93.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.33 earnings per share. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. Equities research analysts forecast that Astera Labs, Inc. will post 1.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Weiss Ratings upgraded Astera Labs from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. UBS Group started coverage on Astera Labs in a research report on Tuesday, April 21st. They set a “neutral” rating and a $180.00 price target on the stock. TD Cowen raised their price target on Astera Labs from $140.00 to $225.00 and gave the company a “hold” rating in a research report on Wednesday. Susquehanna raised their price target on Astera Labs from $155.00 to $230.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Royal Bank Of Canada raised their price target on Astera Labs from $250.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday. Fifteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $229.65.

Insider Transactions at Astera Labs

In related news, Director Manuel Alba sold 183,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $107.61, for a total value of $19,692,630.00. Following the sale, the director directly owned 319,863 shares of the company’s stock, valued at $34,420,457.43. This trade represents a 36.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Sanjay Gajendra sold 94,971 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $11,758,359.51. Following the completion of the sale, the chief operating officer directly owned 1,531,301 shares in the company, valued at $189,590,376.81. The trade was a 5.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,064,888 shares of company stock valued at $150,764,723. 12.50% of the stock is currently owned by corporate insiders.

Key Stories Impacting Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Astera Labs to $280 from $205 and kept an overweight rating, signaling strong confidence in further upside after the company’s latest results. Benzinga
• Positive Sentiment: Needham lifted its price target to $260, while other reports cited positive forecasts from JPMorgan and Stifel, adding to the bullish analyst momentum around ALAB. Astera Labs (NASDAQ:ALAB) Price Target Raised to $260.00 at Needham & Company LLC
• Positive Sentiment: Commentary around the stock highlighted Astera Labs as a long-term momentum name and a beneficiary of AI connectivity demand, suggesting investors see durable growth tied to datacenter buildouts and server interconnect products. Why Astera Labs, Inc. (ALAB) is a Top Momentum Stock for the Long-Term
• Positive Sentiment: Several pieces emphasized strong AI connectivity demand and Scorpio expansion, with upbeat takes on the company’s positioning in the datacenter market helping support the stock. Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised
• Neutral Sentiment: Post-earnings analysis was mixed: bulls pointed to strong growth, but critics noted rising costs, competition, and a premium valuation, which could cap near-term upside. Should Investors Buy, Hold, or Sell ALAB Stock Post Q1 Earnings?
• Neutral Sentiment: Astera Labs’ Q1 2026 earnings transcript kept attention on the company’s strong revenue growth and guidance, but the transcript itself does not add a new catalyst beyond the already reported results. Astera Labs (ALAB) Q1 2026 Earnings Transcript
• Negative Sentiment: The main downside risk is valuation: after a strong run and multiple target hikes, some investors may worry the stock already prices in a lot of future growth.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.